Summary of Key Information:
Reporting Period: Quarter Ended 30th June, 2026 (Q1 FY27)
Nature of Filing: Outcome of Board Meeting and Unaudited Financial Results
Audit Opinion:
Unmodified opinion expressed by statutory auditors M/s. Gokhale & Sathe, Chartered Accountants on both standalone and consolidated financial results.
Key Financial Highlights [All figures in ₹ lakhs]:
Standalone Results:
Revenue from Operations: 40,812 (Q1 FY26: 38,561 | YoY: +5.8%)
Total Income: 41,344
Net Profit: 8,232 (Q1 FY26: -2,807 | Significant improvement)
EPS: ₹8.92 basic and diluted (Q1 FY26: -₹3.04)
Other Equity: 1,846
Consolidated Results:
Revenue from Operations: 46,622
Total Income: Not explicitly specified in consolidated data
Net Profit: Not explicitly specified in consolidated data
EPS: Consolidated EPS data appears corrupted in source text
Segment-wise Performance:
The company has only one primary reportable segment: Pharmaceuticals
Geographical Segment Revenue:
- India: 22,775 (52.9% of total)
- Outside India: 18,037 (47.1% of total)
- Total: 40,812
Exceptional Items:
The Company completed the slump sale of its Ophthalmic Business Division to Sunways (India) Private Limited. The gain on sale of ₹9,734 lakhs has been recognized as an Exceptional Item in the Statement of Profit or Loss.
Corporate Actions:
No dividend declarations, share splits, bonus issues, buybacks, or capital raising activities announced in this filing.
Entities Included in Consolidation:
- Xtend Industrial Designers & Engineers P. Ltd. (100% Subsidiary)
- Indoco Remedies Czech S R O (100% Subsidiary)
- Indoco Remedies UK Ltd. (100% Subsidiary)
- Warren Remedies Private Limited (100% Subsidiary)
- FPP Holding Company, LLC (85% Subsidiary)
Other Significant Information:
Management commentary from Ms. Aditi Panandikar, Managing Director: "The first quarter of the financial year 2026-27 reflects the continued execution of our long-term strategy focused on deliverables from our core businesses despite a dynamic operating environment. The growth in this quarter is due to the resilient Domestic Formulation business, while our international formulations and API businesses continued to make steady progress."
EBITDA to net sales for the quarter was 10.3% at ₹422 mn, compared to 3.8% at ₹148 mn in the same quarter last year.
Company overview: Indoco is a fully integrated, research-oriented pharmaceutical company with turnover of US$175 million, over 6,000 employees, 10 manufacturing facilities (6 for FDFs and 4 for APIs), and facilities approved by USFDA and UK-MHRA.